CD16 is a RANK co-receptor, contributing to the amplification of osteoclast differentiation [65]; this evidence, along with the previous observations, prompted us to evaluate, first, the percentage of monocyte subtypes in a cohort of PBMCs from 35 CLL patients, and second, whether the eventual expansion of a particular subset could be related to the enhanced rate of bone erosion previously reported [8]. The gene discussed is FCGR3A; the disease is B-cell chronic lymphocytic leukemia.